Turning blood into biological insight for Mental Health
OneCare Biotechnologies build AI-powered, blood-tests to guide clinical decision making and treatment recommendation in complex medical disciplines
Bringing precision medicine to psychiatry
Psychiatry remains one of the most biologically complex fields in medicine. Unlike most areas of medicine, psychiatric and clinical neuroscience diagnosis today still relies almost entirely on subjective interviews and behavioral observation rather than measurable biology, making objective diagnosis and effective treatment selection extraordinarily difficult. This complexity carries a steep human and financial cost: patients often cycle through multiple misdiagnoses and ineffective treatments before finding one that works, driving up the burden on healthcare systems, families, and economies worldwide.
OneCare combines blood-based biomarkers with machine learning to give clinicians objective, reproducible signals of psychiatric illness, starting with schizophrenia, with a platform designed to extend to depression, bipolar disorder, and other neuropsychiatric conditions. Our goal is to make this kind of precision diagnostics available at the convenience and speed of a routine blood test, so every patient, regardless of geography or income, can access biologically grounded mental health care.
Starting with schizophrenia
Schizophrenia is a chronic, severe neuropsychiatric disorder that disrupts thought, perception, and behavior, affecting roughly 1% of the global population. We are developing blood-based tests to bring objective, biological evidence to its diagnosis and treatment.
Schizophrenia Detection
We are developing blood-based tests for the detection of schizophrenia, giving clinicians an objective biological signal to support diagnosis alongside clinical assessment.
Treatment-Resistant Schizophrenia
Our tests can also detect whether a patient has treatment-resistant schizophrenia, enabling quicker diagnosis and getting patients onto the right drug at the right time, roughly doubling their chances of successful rehabilitation.
Supporting Drug Development
The same biological signatures that guide clinical decision-making can also improve drug development.
Psychiatric clinical trials often fail because patients with the same diagnosis can have very different underlying biology, making it difficult to identify who is most likely to respond to an investigational therapy.
Our platform enables pharmaceutical partners to stratify patients based on objective molecular profiles, helping enrich clinical trials with the right patient populations, improve signal detection, and increase the likelihood of successful clinical outcomes.
Following regulatory approval, our platform can be deployed as companion diagnostics, helping clinicians identify the patients most likely to benefit from a specific therapy through a simple blood test.